GD2和GD3神经节苷脂作为高级别浆液性卵巢癌的预后生物标志物

GD2 and GD3 gangliosides as prognostic biomarkers in high grade serous ovarian cancer.

作者信息

Levin Gabriel, Matanes Emad, Yasmeen Amber, Meyer Raanan, Brodeur Melica Nourmoussavi, Salvador Shannon, Lau Susie, Saragovi H Uri, Gotlieb Walter

机构信息

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

出版信息

J Gynecol Obstet Hum Reprod. 2025 Jan;54(1):102860. doi: 10.1016/j.jogoh.2024.102860. Epub 2024 Oct 3.

DOI:10.1016/j.jogoh.2024.102860

PMID:39366506

Abstract

OBJECTIVE

Gangliosides GD2 and GD3 have been proposed to be of significance in diagnosis of ovarian masses. We aim to study serum GD2 and GD3 gangliosides as predictors of oncological outcomes among high grade serous (HGS) ovarian cancer (OC).

MATERIALS AND METHODS

A retrospective study including biobanked serum samples of HGS OC treated between 2005 and 2016. Serum GD2 and GD3 concentrations were quantified using indirect ELISA and analyzed with respect to survival.

RESULTS

Sixty patients were included. Patients with GD3>12.8 ng/mL had shorter PFS when compared to patients with lower level; median 31 vs. 67 months, p = 0.005. Patients with GD2> 7.1 ng/mL had shorter median PFS than those with lower level of (23 vs. 52 months, p = 0.024.) Patients with GD3>14.5 ng/mL had shorter OS vs. patients with lower level (median 31 vs. 70 months, p = 0.002). In a Cox regression, following adjustment for age, CA-125, disease stage and age, serum elevated GD3 was independently associated with short PFS (adjusted hazard ratio 2.0, 95 % CI 1.1-3.8, p=.024). In a separate Cox regression, elevated GD2 was independently associated with PFS (adjusted hazard ratio3.0 (1.2-7.7). p=.019. High serum GD3 and GD2 were independently associated with short OS as well.

CONCLUSIONS

High levels of serum GD2 and GD3 in HGS OC were associated with shorter PFS and OS. GD3 is superior to GD2 as a biomarker for prognosis.

摘要

目的

神经节苷脂GD2和GD3被认为在卵巢肿块的诊断中具有重要意义。我们旨在研究血清GD2和GD3神经节苷脂作为高级别浆液性（HGS）卵巢癌（OC）肿瘤学预后的预测指标。

材料与方法

一项回顾性研究，纳入2005年至2016年间接受治疗的HGS OC患者的生物样本库血清样本。使用间接酶联免疫吸附测定法对血清GD2和GD3浓度进行定量，并分析其与生存率的关系。

结果

共纳入60例患者。与GD3水平较低的患者相比，GD3>12.8 ng/mL的患者无进展生存期（PFS）较短；中位数分别为31个月和67个月，p = 0.005。GD2>7.1 ng/mL的患者中位PFS短于GD2水平较低的患者（23个月对52个月，p = 0.024）。与GD3水平较低的患者相比，GD3>14.5 ng/mL的患者总生存期（OS）较短（中位数分别为31个月和70个月，p = 0.002）。在Cox回归分析中，在对年龄、CA-125、疾病分期和年龄进行调整后，血清GD3升高与短PFS独立相关（调整后的风险比为2.0，95%置信区间为1.1 - 3.8，p = 0.024）。在另一项Cox回归分析中，GD2升高与PFS独立相关（调整后的风险比为3.0（1.2 - 7.7），p = 0.019）。高血清GD3和GD2也与短OS独立相关。